

Keep this card with you at all times during treatment and for 2 months after your last ZILBRYSQ dose. Your risk of meningococcal infection may continue for several weeks after your last dose of ZILBRYSQ.

Show this card to the care provider.

If you have any signs or symptoms of meningococcal infection, call your healthcare provider right away. If you can't reach your healthcare provider, seek emergency care immediately.

- Call your healthcare provider or seek emergency care immediately if you have any of these signs and symptoms of meningococcal infection:
- Headache with any of these other symptoms:
 - nausea or vomiting – stiff neck – stiff back – fever
 - Fever with or without a rash
 - Eyes sensitive to light
 - Confusion
- Muscle aches with flu-like symptoms

Carry this Patient Safety Card at all times.

Show this PATIENT SAFETY CARD to any healthcare provider involved in your health care and if you go to the hospital.



- ZILBRYSQ® (zilucoplan) increases your chance of getting a meningococcal infection. This can be an infection of the linings of the brain and spinal cord called meningitis. It can also be an infection of the blood called septicemia. These infections may quickly become life-threatening or fatal if not recognized and treated early.
- Call your healthcare provider or seek emergency care immediately if you have any signs or symptoms of meningococcal infection.

ZILBRYSQ[®]

(zilucoplan) Injection

ZILBRYSQ[®] is a trademark of UCB.

Copyright © 2023, UCB.

All rights reserved. Date of Preparation

September 2023 US-P-ZL-MG-2200005

Important Safety Information for Healthcare Providers

This patient has been prescribed ZILBRYSQ (zilucoplan), a complement component 5 (C5) inhibitor that increases the patient's susceptibility to meningococcal infections caused by *Neisseria meningitidis*.

For more information about ZILBRYSQ, please refer to the Prescribing Information.

PATIENT SAFETY CARD

- Meningococcal infections may rapidly become life-threatening and can be fatal if not diagnosed and treated promptly.
- Evaluate the patient immediately. Withhold administration of ZILBRYSQ in patients who are undergoing treatment for meningococcal infection.
- Contact the healthcare provider who prescribed ZILBRYSQ as soon as possible if you suspect a meningococcal infection in this patient. The prescriber is listed on this card.

Contact the listed ZILBRYSQ prescriber as soon as possible if the patient has signs or symptoms of meningococcal infection.

For more information about ZILBRYSQ, please refer to the Prescribing Information.

Potential cases of meningococcal infections should be reported immediately to UCB, Inc. at 1-844-599-2273

You are encouraged to report other adverse reactions of ZILBRYSQ to UCB Inc. or the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

Patient Name _____

Prescriber Name _____

Prescriber Phone Number _____

Emergency Contact Number _____